1-20 of 49
Jonathan A. Pachter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4127: Combined inhibition of RAF, MEK, and FAK attenuates melanoma brain metastases and prolongs survival in preclinical models

Karly A. Stanley, Jared D. Almazan, Tursun Turapov, David A. Kircher, Gennie L. Parkman, MiKaela N. Field, Katie M. Culver, Christopher M. Stehn, Silvia Coma, Jonathan A. Pachter, Howard Colman, Sheri L. Holmen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4127.
https://doi.org/10.1158/1538-7445.AM2024-4127
Published: 22 March 2024
View articletitled, Abstract 4127: Combined inhibition of RAF, MEK, and FAK attenuates melanoma brain metastases and prolongs survival in preclinical models
Journal Articles

Abstract 3318: GFH375 (VS-7375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy

Feng Yan, Tao Jiang, Tao Liang, Lijian Cai, Leitao Zhang, Xiaoming Xu, Yanhui Zhao, Xiaoling Lan, Xiaohui Zhang, Meng Liu, Qiang Liu, Jinting Gao, Fubo Xie, Xueyan Gao, Li Wang, Jingyang Zhang, Hongcan Ren, Dong Liu, Siyuan Le, Lili Tang, Silvia Coma, Yaofeng Cheng, Nathan Sanburn, Jonathan A. Pachter, Fusheng Zhou, Jiong Lan, Qiang Lu
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3318.
https://doi.org/10.1158/1538-7445.AM2024-3318
Published: 22 March 2024
View articletitled, Abstract 3318: GFH375 (VS-7375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy
Journal Articles

Abstract A091: The RAF/MEK clamp avutometinib as the backbone of therapy for pancreatic cancer: Novel combinations with standard of care chemotherapy, FAK inhibitors, KRAS G12D inhibitors and/or autophagy inhibitors

Silvia Coma, Xiuting Liu, Noah L. Pieper, Wen-Hsuan Chang, Kirsten L. Bryant, Channing J. Der, David G. DeNardo, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2024) 84 (2_Supplement): A091.
https://doi.org/10.1158/1538-7445.PANCA2023-A091
Published: 16 January 2024
View articletitled, Abstract A091: The RAF/MEK clamp avutometinib as the backbone of therapy for pancreatic cancer: Novel combinations with standard of care chemotherapy, FAK inhibitors, KRAS G12D inhibitors and/or autophagy inhibitors
Journal Articles

Abstract C003: RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma

Kian-Haut Lim, Manuel Hidalgo, Mark H. O'Hara, Kristen R. Spencer, Ignacio Garrido-Laguna, David G. DeNardo, Vijeta Bhambhani, Gloria Patrick, Yaofeng Cheng, Silvia Coma, Jonathan A. Pachter, Louis J. Denis
Journal: Cancer Research
Cancer Res (2024) 84 (2_Supplement): C003.
https://doi.org/10.1158/1538-7445.PANCA2023-C003
Published: 16 January 2024
View articletitled, Abstract C003: RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma
Journal Articles

Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Silvia Coma, Miriam Molina Arcas, Julian Downward, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4155.
https://doi.org/10.1158/1538-7445.AM2023-4155
Published: 04 April 2023
View articletitled, Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1
Journal Articles

Abstract 4933: Duvelisib eliminates CLL B Cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a patient-derived xenograft model

Shih-Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Jeffery L. Kutok, Marisa Peluso, Sujata Sharma, David T. Weaver, Jonathan A. Pachter, Kanti R. Rai, Nicholas Chiorazzi
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4933.
https://doi.org/10.1158/1538-7445.AM2023-4933
Published: 04 April 2023
View articletitled, Abstract 4933: Duvelisib eliminates CLL B Cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a patient-derived xenograft model
Journal Articles

Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Adam R. Stewart, Lisa Pickard, Ekta Paranjape, Victoria Sanchez Perez, Sanjib Chowdhury, Stephanie Lustgarten, Silvia Coma, Jonathan A. Pachter, Mark S. Carey, Gabriel DiMattia, Hannah C. Badham, Toby Prout, Mona Parmar, Muneeb Mahmud, Christina Yap, Matthew G. Krebs, Susana Banerjee, Udai Banerji
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3476.
https://doi.org/10.1158/1538-7445.AM2022-3476
Published: 15 June 2022
View articletitled, Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response
Journal Articles

Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203)

Ramaswamy Govindan, Jonathan A. Pachter, Andrew G. Koustenis, Gloria Patrick, Louis J. Denis
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT204.
https://doi.org/10.1158/1538-7445.AM2022-CT204
Published: 15 June 2022
View articletitled, Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203)
Journal Articles

Abstract 1179: Rational combinations with the dual RAF/MEK inhibitor VS-6766 for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or CRAF mutations

Antonella Bacchiocchi, Silvia Coma, Sanjib Chowdhury, Mario Sznol, Ruth Halaban, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1179.
https://doi.org/10.1158/1538-7445.AM2022-1179
Published: 15 June 2022
View articletitled, Abstract 1179: Rational combinations with the dual RAF/MEK inhibitor VS-6766 for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or CRAF mutations
Journal Articles

Abstract 402: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK

Silvia Coma, Sanjib Chowdhury, Julien Dilly, Monica Musteanu, Mariano Barbacid, Andrew J. Aguirre, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 402.
https://doi.org/10.1158/1538-7445.AM2022-402
Published: 15 June 2022
View articletitled, Abstract 402: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK
Journal Articles

Abstract 1263: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition strategy

Silvia Coma, Sanjib Chowdhury, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1263.
https://doi.org/10.1158/1538-7445.AM2021-1263
Published: 01 July 2021
View articletitled, Abstract 1263: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition strategy
Journal Articles

Abstract 1425: Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumors

Silvia Coma, Justine S. Paradis, J Silvio Gutkind, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1425.
https://doi.org/10.1158/1538-7445.AM2021-1425
Published: 01 July 2021
View articletitled, Abstract 1425: Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumors
Journal Articles

Abstract 663: The dual PI3K-δ/PI3K-γ inhibitor duvelisib inhibits signaling and proliferation of solid tumor cells expressing PI3K-δ and/or PI3K-γ

SILVIA COMA, David T. Weaver, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 663.
https://doi.org/10.1158/1538-7445.AM2020-663
Published: 15 August 2020
View articletitled, Abstract 663: The dual PI3K-δ/PI3K-γ inhibitor duvelisib inhibits signaling and proliferation of solid tumor cells expressing PI3K-δ and/or PI3K-γ
Journal Articles

Abstract 6406: FAK and MEK co-targeting: A new multimodal precision therapy for GNAQ-driven uveal melanoma

Justine S. Paradis, Monica Acosta, Nadia Arang, Robert Saddawi-Konefka, Ayush Kishore, Takahito Sugase, Xiaodong Feng, Kris C. Wood, Silvia Coma, Mizue Terai, Takami Sato, Jonathan A. Pachter, J. Silvio Gutkind
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6406.
https://doi.org/10.1158/1538-7445.AM2020-6406
Published: 15 August 2020
View articletitled, Abstract 6406: FAK and MEK co-targeting: A new multimodal precision therapy for GNAQ-driven uveal melanoma
Journal Articles

Abstract CT045: Synergistic anti-tumor efficacy of the dual PI3K-δ/PI3K-γ inhibitor duvelisib with PD-1 blockade in solid tumor and lymphoma models

Silvia Coma, Christopher R. Funk, Shuhua Wang, Edmund K. Waller, David T. Weaver, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT045.
https://doi.org/10.1158/1538-7445.AM2020-CT045
Published: 15 August 2020
View articletitled, Abstract CT045: Synergistic anti-tumor efficacy of the dual PI3K-δ/PI3K-γ inhibitor duvelisib with PD-1 blockade in solid tumor and lymphoma models
Journal Articles

Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers

Rajiv Shinde, Angelika Terbuch, Martin Little, Reece Caldwell, Roopa Kurup, Ruth Riisnaes, Mateus Crespo, Ruth Ruddle, Bora Gurel, Adam Stewart, Jenny King, Mona Parmar, Alison Turner, Florence Raynaud, Muneeb Mahmud, Christina Yap, Jonathan A. Pachter, Gordon B. Mills, Anna Minchom, Juanita Lopez, Susana N. Banerjee, Johann S. de Bono, Matthew Krebs, Udai Banerji
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT143.
https://doi.org/10.1158/1538-7445.AM2020-CT143
Published: 15 August 2020
View articletitled, Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers
Journal Articles

Abstract 1552: Single cell expression analysis of PIK3 genes to direct solid tumor treatment with the dual PI3K-δ,γ inhibitor duvelisib

Samantha Hidy, Jonathan A. Pachter, David T. Weaver
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1552.
https://doi.org/10.1158/1538-7445.AM2020-1552
Published: 15 August 2020
View articletitled, Abstract 1552: Single cell expression analysis of PIK3 genes to direct solid tumor treatment with the dual PI3K-δ,γ inhibitor duvelisib
Journal Articles

Abstract A26: Modeling the ovarian cancer immune response and tumor microenvironment

Duygu Ozmadenci, Jayanth S. Shankara Narayanan, Jacob R. Andrew, Allison M. Barrie, Shulin Jiang, Esra Bilir, Thomas Bertotto, Rebekah R. White, Vijay K. Kuchroo, Jonathan A. Pachter, Dwayne G. Stupack, David D. Schlaepfer
Journal: Cancer Research
Cancer Res (2020) 80 (11_Supplement): A26.
https://doi.org/10.1158/1538-7445.CAMODELS2020-A26
Published: 02 June 2020
View articletitled, Abstract A26: Modeling the ovarian cancer immune response and tumor microenvironment
Journal Articles

Abstract 1991: Vulnerability of platinum-resistant ovarian cancer to FAK inhibition

Carlos J. Diaz Osterman, Lisa M. Bean, Florian J. Sulzmaier, Kristin N. Taylor, Shulin A. Jiang, Isabelle Tancioni, Kristen Anderson, Christine Jean, Xiao Lei Chen, Elizabeth G. Kleinschmidt, Vihren N. Kolev, David T. Weaver, Jonathan A. Pachter, Denise C. Connolly, Alfredo Molinolo, David D. Schlaepfer
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1991.
https://doi.org/10.1158/1538-7445.AM2018-1991
Published: 01 July 2018
View articletitled, Abstract 1991: Vulnerability of platinum-resistant ovarian cancer to FAK inhibition
Journal Articles

Abstract 568: FAK/PYK2 inhibition enhances immune checkpoint inhibitor efficacy

Yan Wang, Jennifer E. Ring, Kam Sprott, David T. Weaver, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 568.
https://doi.org/10.1158/1538-7445.AM2016-568
Published: 15 July 2016
View articletitled, Abstract 568: FAK/PYK2 inhibition enhances immune checkpoint inhibitor efficacy